2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1516

Quality Improvement in Elderly Patients with Rheumatoid Arthritis: Pharmacotherapy and Identification of Cognitive Dysfunction

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1720

Quantitative Assessment of Bone Marrow Fat Using Magnetic Resonance Imaging in Patients with Spondyloarthropathy

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1314

Quantitative MRI Measurement of Tenosynovitis Demonstrates Differing Responses of Synovitis and Tenosynovitis after RA Treatment

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1459

Racial Comparisons of Children with Idiopathic Uveitis: Results from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1423

Racial Disparities in Pain and Function after Total Knee Arthroplasty in the United States: A Systematic Literature Review

Orthopedics, Low Back Pain and Rehabilitation Poster

9:00AM-11:00AM: Abstract Number: 1279

Racial Variation in Total Knee Replacement in a Diverse Community-Based Clinical Trial

Health Services Research Poster II (ACR): Healthcare Access, Patterns of Medication Use and Workforce Considerations

9:00AM-11:00AM: Abstract Number: 1312

Radiocarpal Cartilage Matrix Changes 3-Months after Anti-TNF Treatment for Rheumatoid Arthritis – Feasibility Study Using MR T1ρ� Imaging

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1731

Radiographic Damage of Facet Joints and Vertebral Bodies in the Cervical Spine in Patients with Ankylosing Spondylitis Treated with TNF Inhibitors

Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

9:00AM-11:00AM: Abstract Number: 1670

Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1323

Reaching Consensus – Volumetric Joint Space Width Calculations in Finger Joints of Arthritis Patients

Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

9:00AM-11:00AM: Abstract Number: 1513

Reactivation of Hepatitis B-Infection in German Patients with Inflammatory Rheumatic Diseases Treated with Biologics – a Monocentric Analysis Involving 1107 Patients

Rheumatoid Arthritis - Clinical Aspects Poster II

9:00AM-11:00AM: Abstract Number: 1809

Real Life Implementation of Lupus Nephritis Randomized Controlled Trials

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1762

Reciprocal Roles of Intestinal Microbiota in the Pathogenesis of Organ-Specific Autoimmune Diseases in a Lymphopenia-Induced Autoimmunity Mouse Model

Systemic Lupus Erythematosus - Animal Models Poster I

9:00AM-11:00AM: Abstract Number: 1832

Recurrence-Rate of Thrombotic Events in SLE Patients Negative for Antiphospholipid Antibodies

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1143

Reduced Hydrogen Sulfide Synthesis in the Joint, a New Player in the Pathogenesis of Osteoarthritis

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].